Lv3
390 积分 2024-02-17 加入
Adverse outcomes and high incidence of therapy-related neoplasms in patients with the t(16;21)/ RUNX1 :: RUNX1T3 fusion
1个月前
已完结
Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma
2个月前
已完结
Enasidenib plus venetoclax in patients with IDH2-mutated relapsed or refractory acute myeloid leukaemia or myelodysplastic syndrome (ENAVEN-AML): a multicentre, single-arm, phase 1b/2 trial
2个月前
已完结
Old drug, new use: Recent advances for G-CSF
2个月前
已完结
A wearable osmotic microneedle patch provides high-capacity sustained drug delivery in animal models
5个月前
已完结
Dynamic evolution of venetoclax resistance in acute myeloid leukemia unveiled by longitudinal single-cell RNA-seq
5个月前
已完结
Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of a phase 3, open-label, randomised, controlled trial
5个月前
已关闭
Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial
6个月前
已完结
IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score
6个月前
已完结
The conundrum of drug development in higher-risk MDS: Lessons learned from recently failed phase 3 clinical trials
6个月前
已关闭
皖公网安备34019202002308
